Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

NCT01084837 | Completed Phase 2 DMC

• 1 other identifier: RENVEL
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 11

Brief Summary

Primary outcome measure:

• Analyze the efficacy (in order to evaluate the response) of Bortezomib/Dexamethasone treatment Secondary outcome measures:
• Study the speed of response and the response rate (M component in serum and urine protein) after each bortezomib/dexamethasone cycle
• Compare the efficacy of the bortezomib/dexamethasone therapy against the therapy without bortezomib
• Reversibility of renal failure
• Predictive value in the light chain determination for response and reversibility of renal failure
• Early morbidity (\< 2 months)
• Progression-free survival
• Overall survival The safety outcome consists in:
• Determining the safety and tolerance of VELCADE/Dexamethasone, according to the toxicity criteria of clinical and laboratory events

Conditions

Multiple Myeloma

Keywords

Multiple myeloma; Renal failure

Outcome Measures

Primary Outcomes (1)

• Efficacy

  Analyze the efficacy (in order to evaluate the response) of Bortezomib/Dexamethasone treatment

  2 years

Secondary Outcomes (3)

• Progression-free survival

  2 years

• Overall survival

  4 years

• Safety

  1 year

Interventions

velcade DRUG

INDUCTIoN (Cycles 1-4) * Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment * Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days) For patients wich is not planned autotransplantation, add: Cycles 5-8 * Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment * Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days) EXTENSION TREATMENT(Cycles 9-12) * Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22 * Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient must, according with investigator criteria, be able to comply with all the protocol requirements
• The patient or legal representative must sign voluntarily the informed consent before the performance of any study related procedure, not part of usual medical care, with the knowledge that can leave the study the moment he/she wants, without prejudice to later medical care
• years and older
• Patients with newly diagnosed symptomatic multiple myeloma43 which hasn't been treated previously with any chemotherapy used for this disease (see Annex 8)
• Patient with a measurable or evaluable disease, defined as follows:
• For secretor multiple myeloma, measurable disease is defined as any quantifiable serum monoclonal protein value of IgG\>10g/l or IgA \> 5 g/l and, where applicable, urine light-chain excretion of ≥ 200 mg/24 hours
• For oligo or non-secretor multiple myeloma, measurable disease is defined by the presence of soft tissue plasmocytomas (not bone) determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan). In patients with low secretor multiple myeloma, the serum and/or urine M-protein measurements are very low and difficult to follow for response assessment. In patients with non-secretor multiple myeloma, there is no M-protein in serum or urine by immunofixation
• ECOG performance status ≤ 2 (see Appendix 5)
• Patient has a life-expectancy \>3 months
• Glomerular filtration calculated with MDRD \<50 ml/min
• Patient has the following laboratory values during the 14 days before first dose:
• Platelet count ≥ 50x109/l
• Absolute neutrophil count (ANC) ≥ 0.75 x 10 9/ L
• Corrected serum calcium (see Appendix 15) ≤ 14mg/dl
• Aspartate transaminase (AST): ≤ 2,5 x upper limit of normal

You may not qualify if:

• Glomerular filtration calculated with MDRD ≥ 50ml/min
• Asymptomatic MM with renal failure from unrelated causes
• Prior Velcade therapy
• Patients previously received treatment to Multiple Myeloma
• Patient with platelet count ≤ 50 x 109/l within 14 days before enrolment
• Patient with absolute neutrophil count ≤ 0,75x109/l within 14 days before enrolment
• Patients with Grade 2 peripheral neuropathy within 14 days before enrolment
• Patient has hypersensitivity to bortezomib, boron or mannitol
• Patient has received other investigational drugs within 14 days before enrolment
• Patient is known to be seropositive for the human immunodeficiency virus (HIV)
• Patient had a myocardial infarction within 6 months before of enrolment or has Class III or IV heart failure (New York Heart Association \<NYHA\>), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiography evidence of acute ischemia or active conduction system abnormalities, or other heart condition which, according with the specialist, can result in heart failure
• Patient is enrolled in another clinical research study and/or is receiving an investigational agent for any reason
• Patients with diffuse pulmonary disease and/or pericardial disease
• Pregnancy or breast-feed women and women of childbearing age that don't accept to use anticonceptive methods since beginning during all the study until 30 days after last cycle treatment. Fertile male patients must use effective form of contraception since enrolment, during and until 30 days after last cycle study treatment
• Patient with a previous clinical history of another malign illness except for squamous cell carcinoma or skin cancer or cervical or breast cancer) except the patient could be free of symptoms during ≥ 5 years

Sponsors & Collaborators

• PETHEMA Foundation: lead

Study Sites (11)

Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Location

Hospital Clinic

Barcelona, Barcelona, Spain

Location

Hospital de Sant Pau

Barcelona, Barcelona, Spain

Location

Hospital 12 de Octubre

Madrid, Madrid, Spain

Location

Hospital Clínico San Carlos

Madrid, Madrid, Spain

Location

Hospital Ramón y Cajal

Madrid, Madrid, Spain

Location

Hospital Universitario

Salamanca, Salamanca, Spain

Location

Hospital General

Segovia, Segovia, Spain

Location

Hospital Universitario de Canarias

Santa Cruz de Tenerife, Tenerife, Spain

Location

Hospital La Fe

Valencia, Valencia, Spain

Location

Hospital Lozano Blesa

Zaragoza, Zaragoza, Spain

Location

Related Links

• web Haematology Spanish Association

MeSH Terms

Conditions

Multiple Myeloma; Renal Insufficiency

Interventions

Bortezomib

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Boronic Acids; Acids, Noncarboxylic; Acids; Inorganic Chemicals; Boron Compounds; Organic Chemicals; Pyrazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 7, 2010
• First Posted: March 11, 2010
• Study Start: March 1, 2010
• Primary Completion: September 1, 2012
• Study Completion: December 1, 2013
• Last Updated: September 17, 2015

Record last verified: 2015-09

Locations

ES (11)